Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

James R. Berenson; Alan Lichtenstein; Lester Porter; Meletios A Dimopoulos; Roldolfo Bordoni; Sebastian George; Allan Lipton; Alan Keller; Oscar Ballester; Michael J. Kovacs; Hilary Blacklock; Richard H. Bell; Joseph F. Simeone; Dirk J. Reitsma; Maika Heffernan; John J. Seaman; Robert Knight

doi:10.1056/nejm199602223340802

Abstract

1 min read

Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.

Related publications

Article1998

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Meletios A Dimopoulos, Rodolfo Bordoni, Saby George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hillary Blacklock, R. Bell, Joseph F. Simeone, Dirk J. Reitsma, M Heffernan, John J. Seaman, Robert Knight

Article2006

Zoledronic Acid May Improve Survival Compared to Pamidronate in Patients with MM and High BALP Levels: Univariate and Multivariate Models of Hazard Ratios.

James R. Berenson, Meletios A Dimopoulos, YinMiao Chen

Article2006

Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels

James R. Berenson, N. Shirina, Y. M. Chen, Meletios A Dimopoulos

Article2025

Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice

Ioannis Ntanasis‐Stathopoulos, Vassilis Koutoulidis, Panagiotis Malandrakis, Despina Fotiou, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Nikolaos Kanellias, Foteini Theodorakakou, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Lia A. Moulopoulos, Maria Gavriatopoulou

Article2005

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Meletios A Dimopoulos, Efstathios Kastritis, Lia A. Moulopoulos, Ioannis Melakopoulos, Αchilles Anagnostopoulos, Dimitra Gika, George Bozas, Vassiliki Koutsoukou, Aristotelis Bamias